Oculus' (OCLS) CEO Jim Schutz on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 7:10PM CST
OCLS: 1.64 (+0.16)
Oculus Innovative Sciences (OCLS) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 13, 3:25PM CST
OCLS: 1.64 (+0.16)
Oculus Innovative Sciences beats by $0.10, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:13PM CST
OCLS: 1.64 (+0.16)
Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015
GlobeNewswire - Thu Nov 13, 3:08PM CST
-- Total revenue of $3.3 million for the second quarter
OCLS: 1.64 (+0.16), RTGN: 3.83 (-0.17)
Oculus Innovative Sciences Commercializes Microcyn(R)-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europe
GlobeNewswire - Tue Nov 11, 4:04AM CST
-- New GramaDerm(TM) Solution and Hydrogel to be introduced at Medica Trade Fair on November 12-15 in Dusseldorf, Germany
OCLS: 1.64 (+0.16)
Oculus Hydrogel gets CE Mark clearance
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 7:34AM CST
OCLS: 1.64 (+0.16)
Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Scar Management Hydrogel
GlobeNewswire - Tue Nov 04, 3:59AM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 36 countries, today announced the issuance of a new CE Mark in Europe for Microcyn(R)-based Epicyn(TM) Hydrogel. Epicyn Hydrogel is indicated for the management and reduction of new and existing hypertrophic and keloid scars, assisting with moistening while forming a protective barrier against physical, chemical and microbial invasion of the scar.
OCLS: 1.64 (+0.16)
Oculus Innovative Sciences wins CE Mark for marketing of Microcyn Atopic Dermatitis Hydrogel in Europe
M2 - Fri Oct 31, 11:42AM CDT
Healthcare company Oculus Innovative Sciences (NasdaqCM:OCLS) revealed on Thursday the receipt of a new CE Mark in Europe for Microcyn-based Pediacyn Hydrogel.
OCLS: 1.64 (+0.16)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 8:18AM CDT
KNDI: 12.45 (-0.40), ALU: 3.35 (-0.08), CDTI: 1.91 (-0.09), VSR: 2.99 (-0.03), NBG: 1.79 (-0.01), ARAY: 6.95 (+0.04), GLUU: 3.88 (unch), OCLS: 1.64 (+0.16), CEMI: 4.30 (+0.03), TTWO: 28.14 (+1.07), PRXL: 54.13 (-0.87), RDN: 16.68 (-0.23), BBD: 12.83 (-0.61), NVAX: 5.76 (-0.17), APT: 2.64 (-0.03), BBSI: 23.63 (+0.58), LAKE: 10.79 (-0.40), GOL: 5.43 (-0.24), TASR: 23.19 (unch), AUY: 3.96 (-0.10), PCRX: 91.11 (-2.12), ITUB: 12.62 (-0.61)
Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Atopic Dermatitis Hydrogel
GlobeNewswire - Thu Oct 30, 7:12AM CDT
? New Pediacyn(TM) Hydrogel to be Introduced at Medica Education Conference on November 12-15 in Dusseldorf, Germany
OCLS: 1.64 (+0.16)
Oculus Innovative Sciences Announces Fiscal Second Quarter 2015 Financial Results and Conference Call
GlobeNewswire - Thu Oct 30, 7:08AM CDT
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal second quarter 2015, ended September 30, 2014, will be released after the U.S. markets close on November 13, 2014. The earnings release will be followed by a conference call at 1:30 p.m. PT (4:30 p.m. ET) on November 13, 2014, to discuss fiscal second quarter results.
OCLS: 1.64 (+0.16)
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of Four New Patents for Microcyn(R) Technology
GlobeNewswire - Tue Sep 16, 7:10AM CDT
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries, today announced the allowance of four new U.S. and international patents for the company's flagship technology, Microcyn(R). These include a U.S. patent for treatment of second- and third-degree burns; U.S. and Canadian patents for treatment of peritonitis; and a Chinese patent for the Microcyn solution and its methods of use. The U.S. patent directed to peritonitis issued today as U.S. Patent No. 8,834,445, while the second- and third-degree burn U.S. patent will issue on September 23, 2014. The exact dates of issuance for the Chinese and Canadian patents are yet to be determined.
OCLS: 1.64 (+0.16)
Oculus Innovative Sciences Introduces Microcyn(R)-Based Over-the-Counter Advanced Scar Management Hydrogel in United States
GlobeNewswire - Wed Sep 10, 7:09AM CDT
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries, today introduced Regenacyn(TM) Advanced Scar Management Hydrogel into the U.S. over-the-counter market. Formulated from the company's flagship Microcyn(R) Technology platform, Regenacyn is a customized solution designed to address the underserved consumer scar management market.
OCLS: 1.64 (+0.16)
Oculus Innovative Sciences Reports Revenues of $3.4 Million and Net Loss of $70,000 for First Quarter of Fiscal 2015
GlobeNewswire - Thu Aug 07, 3:42PM CDT
-- Net loss of $70,000, reduced $1.6 million from same period last year
OCLS: 1.64 (+0.16), RTGN: 3.83 (-0.17)
Oculus Innovative Sciences Announces Fiscal First Quarter 2015 Financial Results and Conference Call
GlobeNewswire - Thu Jul 24, 7:41AM CDT
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal first quarter 2015, ended June 30, 2014, will be released after the U.S. markets close on August 7, 2014. The earnings release will be followed by a conference call at 1:30 p.m. PT (4:30 p.m. ET) on August 7, 2014, to discuss fiscal first quarter results.
OCLS: 1.64 (+0.16)
Scar Treatment Market to 2018: Gels, Creams, Oils and Sprays & Invasive Surgical Treatment, Laser Treatment, Elastic Wraps and Gel Sheets
M2 - Wed Jul 16, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c4tlhl/global_scar) has announced the addition of the "Global Scar Treatment Market 2014-2018" report to their offering. Scar treatment products are applied on a scar to treat, heal, and conceal the scar. Products such as gels, creams, oils, and sprays are available as OTC products or are prescribed to treat scars. They are an alternative to invasive surgical treatment, laser treatment, elastic wraps, and gel sheets. Scar treatment application products are easy to use and cost-effective in comparison with invasive treatments. The Global Scar Treatment market can be divided into three segments: Burn Scars, Post-surgical Scars Other than Burn Scars, and Others. Burn scars, also known as hypertrophic scars, stay within the area of the original burn. The treatment of post-surgical scars varies with the degree of scarring. The treatment removes the scars caused by minor surgeries such as appendectomy or Caesarean section scars. Some scars can be hypersensitive and decrease ability to move. The Others segment includes scar treatment for aesthetic reasons such as the reduction in the appearance of acne scars. The Global Scar Treatment market is driven by many factors, one of which is an increase in appearance-consciousness among consumers. Scars leave an undesirable mark on the skin, which has a profound impact on the physical and mental well-being of a person. There has been an increase in the desire to maintain flawless skin, which is leading to an increase in the number of personal care and pharmaceutical scar treatment products. The report states that the risk of side effects is one of the major challenges. Scar treatment products may contain harmful chemicals that could cause side effects. Therefore, consumers are more concerned about the ingredients in these products. Some vendors are unable to meet the expectations of customers when it comes to safety standards. Key Vendors - CCA Industries Inc. - Merz Pharmaceuticals GmbH & Co. KGaA - Oculus Innovative Sciences Inc. - Pacific World Corp. Other Prominent Vendors - Avita Medical Ltd. - Enaltus LLC - Quantum Inc. - Revitol Corp. - Scarguard Labs LLC - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/c4...lobal_scar
CAW: 3.54 (+0.02), OCLS: 1.64 (+0.16), VRX.TO: 160.64 (+0.46)
Advanced Wound Care Markets Worldwide
M2 - Thu Jun 26, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/crcd5q/advanced_wound) has announced the addition of the "Advanced Wound Care Markets Worldwide" report to their offering. Advanced Wound Care Markets The wound care industry is an incredibly diverse and highly competitive arena that is ever-changing. Kalorama Information feels that the market will continue to expand over the long term due to an aging population, longer life expectancies, and an increasing number of sicker patients across all care settings. This report, Advanced Wound Care Markets, provides breakouts of the market by category, including the following: - Skin Ulcers (Management, Moist Dressing, Negative Pressure Wound Therapy, Biological Dressings, Pressure Relief) - Burns Wound Care Market (Anti-Infectives, Management, Moist Dressing, Biological Dressings, Pressure Relief) - Surgical and Trauma Wounds (Wound Closure, Anti-Infectives, Moist Dressing, Biological Dressing, Miscellaneous Surgical and Trauma Wound Treatments) Wound Care Clinics The information and analysis presented in this report are based on extensive surveys of senior management in the wound care market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct over 100 face to face, telephone and email interviews with industry executives and product managers to validate and obtain expert opinion on current and future trends in the wound care industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections. - 3M Health Care - ABL Medical, LLC - ACELL, INC - Alliqua Biomedical, Inc - Amniox Medical - Angelini Pharma, Inc - Argentum Medical, LLC - ArjoHuntleigh - Arobella Medical, LLC - Baxter Bioscience - B. Braun/Aesculap, Inc. - BSN medical - Celleration - Coloplast A/S - ConvaTec, Ltd. - Covidien, Ltd - CryoLife, Inc. - Curaline, Inc - Derma Sciences - DeRoyal Industries - EHOB, Inc - Ethicon, Inc - GlaxoSmithKline Plc - Hartmann Group - Hill-Rom Company, Inc. - Hollister Wound Care LLC - Integra Life Sciences - Johnson & Johnson - Kinetic Concepts, Inc. (KCI) - LifeBond Ltd - Lohmann and Rauscher GmbH - Marine Polymer Technologies, Inc. - Medline Industries - MiMedx - Molnlycke HealthCare - MPM Medical, Inc - Oculus Innovative Sciences, Inc - Organogenesis, Inc - Osiris Therapeutics, Inc - Pfizer, Inc. - Shire Plc - Smith & Nephew, Plc - Soluble Systems, LLC - Southwest Technologies - Spiracur, Inc - SteadMed Medical - Stryker Corp For more information visit http://www.researchandmarkets.com/research/cr...nced_wound
DSCI: 8.60 (-0.20), SNN: 32.48 (-0.41), JNJ: 104.43 (-2.29), SHPG: 213.70 (-0.41), PFE: 30.95 (-0.70), COV: 100.49 (-1.36), OSIR: 12.92 (-0.04), GSK: 42.42 (-0.93), CRY: 10.40 (+0.12), OCLS: 1.64 (+0.16), SYK: 92.00 (-1.41)
Why Oculus Innovative Sciences (OCLS) Stock Is Lower In After-Hours Trading
at The Street - Thu Jun 12, 4:06PM CDT
Oculus Innovative Sciences (OCLS) stock is down in after-hours trading after reporting a 37% drop in revenue for its fiscal fourth quarter.
OCLS: 1.64 (+0.16)
Oculus Innovative Sciences Reports Revenues of $2.9 Million and Net Income of $7.5 Million for Fourth Quarter of Fiscal 2014 Primarily Due to Accounting Treatment of Ruthigen IPO Transaction
GlobeNewswire - Thu Jun 12, 3:05PM CDT
-- Oculus' subsidiary, Ruthigen, completes IPO, raising net proceeds of approximately $15.5 million
OCLS: 1.64 (+0.16), RTGN: 3.83 (-0.17)
Oculus Innovative Sciences Announces Board of Directors Restructuring Following Ruthigen IPO
GlobeNewswire - Wed Apr 02, 8:43AM CDT
-- Board Committees Restructured
RTGN: 3.83 (-0.17), OCLS: 1.64 (+0.16)